Faruqi & Faruqi, LLP Issues Warning to Inovio Pharmaceuticals Investors About Class Action Deadline

Shareholder Alert for Inovio Pharmaceuticals

Inovio Pharmaceuticals has recently come under scrutiny as Faruqi & Faruqi, LLP, a prominent national securities law firm, investigates potential legal claims against the company. Investors who suffered financial losses as a result of investing in Inovio might find themselves eligible for participating in a securities class action lawsuit. The critical deadline for filing to be recognized as a lead plaintiff is set for April 7, 2026.

Legal Concerns Surrounding Inovio Pharmaceuticals

The complaints suggest that Inovio and its executives may have violated federal securities laws through misleading or false statements. They allegedly failed to adequately disclose that their CELLECTRA device had manufacturing deficits, raised concerns about the INO-3107 Biologics License Application (BLA) submission timeframe, and misrepresented the regulatory prospects of the INO-3107 treatment.

On December 29, 2025, the U.S. Food and Drug Administration (FDA) announced it accepted Inovio's BLA for ONO-3107, intended for treating recurrent respiratory papillomatosis. However, they indicated that the submitted information was insufficient for accelerated approval under existing regulations, disappointing many investors and causing the stock price to plummet by 24.45%, ending the day at $1.73 per share.

The Role of Shareholders

Investors who purchased Inovio shares between October 10, 2023, and December 26, 2025, are particularly affected and encouraged to reach out to counsel for possible legal actions. The role of the lead plaintiff is vital; this individual will act on behalf of all members within the class, providing direction and oversight for the litigation.

In order to become the lead plaintiff, investors should be representative of the group and able to manage the proceedings. Those who choose not to serve do not lose the capability to receive any recovery if the court rules in favor of the plaintiff class.

Encouragement for Whistleblowers

Faruqi & Faruqi also encourages past employees, whistleblowers, and others with knowledge of Inovio's internal practices to come forward. Their insights could provide valuable evidence and support the investigation process.

To gain more understanding or to see if you are eligible for recovery, visit Faruqi & Faruqi's official website or contact their representative directly, Josh Wilson, via phone at 877-247-4292 or 212-983-9330 (Ext. 1310).

As the situation unfolds, it remains essential for investors to stay informed and consider their options moving forward. The unfortunate circumstances surrounding Inovio Pharmaceuticals underscore the critical responsibilities companies have to their investors, and the legal recourse available to those who may have been wronged.